"Go upstream, young man": lessons learned from the p38 saga

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) treatment benefits from orally active small-molecule drugs.
• Signal transduction inhibitors are a key focus for RA drug development.
• p38alpha, a regulator of proinflammatory cytokines, is a logical target for RA.

Purpose of the Study:

• To provide perspective on p38alpha inhibitor studies in RA.
• To explain the limited efficacy of selective p38alpha blockers.
• To suggest alternative strategies for RA treatment.

Main Methods:

• Review and analysis of existing studies on p38alpha inhibitors in RA.
• Evaluation of signal transduction pathways involved in RA pathogenesis.
• Comparison of efficacy data for different kinase inhibitors.

Main Results:

• Selective p38alpha inhibitors have demonstrated limited efficacy in RA.
• The failure of p38alpha blockers may be due to targeting downstream effectors.
• Efficacy of Syk and JAK inhibitors suggests alternative strategies.

Conclusions:

• Targeting kinases higher in the signaling cascade may be more effective for RA.
• Less selective kinase inhibitors could offer improved therapeutic outcomes in RA.
• Further research into alternative signal transduction targets is warranted for RA.